{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007186","form_type":"8-K","ticker":null,"cik":"0001267813","company_name":"MARINUS PHARMACEUTICALS, INC.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.658687+00:00","generated_at":"2026-06-02T08:47:23.508934+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Marinus Q1 ZTALMY rev $7.5M (+125% YoY); cost cuts extend cash runway to Q1 2025; RAISE data summer","bullets":["ZTALMY net product revenue $7.5M vs $3.3M YoY; full-year guidance raised to $33-35M from $32-34M.","Phase 3 TrustTSC enrollment completes mid-May; topline data expected H1 Q4 2024; sNDA submission target April 2025.","Phase 3 RAISE (IV ganaxolone in RSE) enrolled 100 patients; topline results early summer 2024; RAISE II stopped.","Company reduced workforce ~20%, stopped RAISE/RAISE II enrollment, deferred IV ganaxolone manufacturing; cash $113.3M.","Net loss $38.7M ($0.68/sh) vs $34.7M ($0.67/sh) in Q1 2023; total GAAP operating expenses guided $135-140M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007186","json":"https://secwatch.observer/filing/0001558370-24-007186.json","markdown":"https://secwatch.observer/filing/0001558370-24-007186.md","text":"https://secwatch.observer/filing/0001558370-24-007186.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267813/000155837024007186/0001558370-24-007186-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267813/000155837024007186/mrns-20240508x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T08:47:23.508934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"36665b04aa1703f9559cecd925c08e289f71cfc8","claim":"MARINUS PHARMACEUTICALS, INC. reported first quarter ended March 31, 2024 results: revenue $7.5 million. Guidance raised.","evidence_excerpt":"(EX-99.1) --- ​ Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results ​ ● ZTALMY ® (ganaxolone) Q1 2024 net product revenue of $7.5 million representing strong growth of 125% versus Q1 2023 ● Increased full year 2024 projected U.S. ZTALMY net product revenues to between $33 and $35 million ● Enrollment to be","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000155837024007186/0001558370-24-007186-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$7.5 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}